文献速递物质与行为成瘾会诊联络精神医学

完全接种疫苗的物质使用障碍患者COVID-19突破感染风险增加

Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021.
PubMed 文献 · World Psychiatry · 2021-10-05

物质使用障碍患者突破感染风险为6.8%-7.8%,显著高于非患者的3.6%(p<0.001);匹配共病和社会经济因素后,除大麻使用障碍(HR=1.55)外差异消失。突破感染后住院风险22.5% vs 1.6%,死亡风险1.7% vs 0.5%。

要点

  • 完全接种的物质使用障碍患者突破感染风险显著高于非患者(6.8%-7.8% vs 3.6%)。
  • 匹配共病和社会经济因素后,仅大麻使用障碍仍与突破感染风险升高独立相关(HR=1.55)。
  • 突破感染后住院风险22.5% vs 1.6%,死亡风险1.7% vs 0.5%。

核心结论

  • 完全接种疫苗的物质使用障碍患者COVID-19突破感染风险显著高于非物质使用障碍人群,主要归因于共病和社会经济健康决定因素的更高患病率。
  • 物质使用障碍患者突破感染后住院和死亡风险显著高于未突破感染者。

研究设计与样本

  • 基于人群的队列研究,使用美国TriNetX Analytics网络平台63家医疗机构的去标识化电子健康记录。

主要发现

  • 物质使用障碍患者突破感染风险从烟草使用障碍的6.8%到大麻使用障碍的7.8%,均显著高于非物质使用障碍人群的3.6%(p<0.001)。
  • 控制人口学特征(年龄、性别、种族)和疫苗类型后,除烟草使用障碍外所有物质使用障碍亚型突破感染风险仍显著升高,可卡因和大麻使用障碍最高(HR=2.06,95%CI:1.30-3.25;HR=1.92,95%CI:1.39-2.66)。
  • 匹配终生共病和不良社会经济健康决定因素后,除大麻使用障碍(HR=1.55,95%CI:1.22-1.99)外,物质使用障碍与非物质使用障碍人群突破感染风险无显著差异。
  • 物质使用障碍患者中,接种Pfizer疫苗者突破感染风险高于接种Moderna疫苗者(HR=1.49,95%CI:1.31-1.69)。
  • 突破感染队列住院风险22.5%,非突破感染队列1.6%(RR=14.4,95%CI:10.19-20.42);死亡风险分别为1.7%和0.5%(RR=3.5,95%CI:1.74-7.05)。

临床怎么用

  • 对完全接种疫苗的物质使用障碍患者应加强突破感染监测和预防措施,尤其关注大麻使用障碍患者。
  • 物质使用障碍患者突破感染后住院和死亡风险高,需及早识别和干预。

局限性

  • 研究为观察性设计,可能存在残余混杂。
  • 匹配共病和社会经济因素后多数亚型风险差异消失,提示这些因素是主要中介。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individuals with substance use disorders (SUDs) are at increased risk for COVID-19 infection and for adverse outcomes of the infection. Though vaccines are highly effective against COVID-19, their effectiveness in individuals with SUDs might be curtailed by compromised immune status and a greater likelihood of exposures, added to the waning vaccine immunity and the new SARS-CoV-2 variants. In a population-based cohort study, we assessed the risk, time trends, outcomes and disparities of COVID-19 breakthrough infection in fully vaccinated SUD patients starting 14 days after completion of vaccination. The study included 579,372 individuals (30,183 with a diagnosis of SUD and 549,189 without such a diagnosis) who were fully vaccinated between December 2020 and August 2021, and had not contracted COVID-19 infection prior to vaccination. We used the TriNetX Analytics network platform to access de-identified electronic health records from 63 health care organizations in the US. Among SUD patients, the risk for breakthrough infection ranged from 6.8% for tobacco use disorder to 7.8% for cannabis use disorder, all significantly higher than the 3.6% in non-SUD population (p<0.001). Breakthrough infection risk remained significantly higher after controlling for demographics (age, gender, ethnicity) and vaccine types for all SUD subtypes, except for tobacco use disorder, and was highest for cocaine and cannabis use disorders (hazard ratio, HR=2.06, 95% CI: 1.30-3.25 for cocaine; HR=1.92, 95% CI: 1.39-2.66 for cannabis). When we matched SUD and non-SUD individuals for lifetime comorbidities and adverse socioeconomic determinants of health, the risk for breakthrough infection no longer differed between these populations, except for patients with cannabis use disorder, who remained at increased risk (HR=1.55, 95% CI: 1.22-1.99). The risk for breakthrough infection was higher in SUD patients who received the Pfizer than the Moderna vaccine (HR=1.49, 95% CI: 1.31-1.69). In the vaccinated SUD population, the risk for hospitalization was 22.5% for the breakthrough cohort and 1.6% for the non-breakthrough cohort (risk ratio, RR=14.4, 95% CI: 10.19-20.42), while the risk for death was 1.7% and 0.5% respectively (RR=3.5, 95% CI: 1.74-7.05). No significant age, gender and ethnic disparities for breakthrough infection were observed in vaccinated SUD patients. These data suggest that fully vaccinated SUD individuals are at higher risk for breakthrough COVID-19 infection, and this is largely due to their higher prevalence of comorbidities and adverse socioeconomic determinants of health compared with non-SUD individuals. The high frequency of comorbidities in SUD patients is also likely to contribute to their high rates of hospitalization and death following breakthrough infection.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wang L, Wang Q, Davis PB, et al. Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry. 2021. PMID: 34612005. doi:10.1002/wps.20921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。